Skip to main content

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Nutalai, Rungtiwa, Zhou, Daming, Tuekprakhon, Aekkachai, Ginn, Helen M., Supasa, Piyada, Liu, Chang, Huo, Jiandong, Mentzer, Alexander J., Duyvesteyn, Helen M.E., Dijokaite-Guraliuc, Aiste, and others. (2022) Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, . ISSN 0092-8674. (doi:10.1016/j.cell.2022.05.014) (KAR id:95166)

PDF Author's Accepted Manuscript
Language: English
Download (49MB) Preview
[thumbnail of PIIS0092867422005980.pdf]
Preview
This file may not be suitable for users of assistive technology.
Request an accessible format
Official URL:
https://doi.org/10.1016/j.cell.2022.05.014

Abstract

Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we compare neutralization of Omicron BA.1, BA.1.1 and BA.2. BA.2 RBD has slightly higher ACE2 affinity than BA.1 and slightly reduced neutralization by vaccine serum, possibly associated with its increased transmissibility. Neutralization differences between sub-lineages for mAbs (including therapeutics) mostly arise from variation in residues bordering the ACE2 binding site, however, more distant mutations S371F (BA.2) and R346K (BA.1.1) markedly reduce neutralization by therapeutic antibody Vir-S309. In-depth structure-and-function analyses of 27 potent RBD-binding mAbs isolated from vaccinated volunteers following breakthrough Omicron-BA.1 infection reveals that they are focussed in two main clusters within the RBD, with potent right-shoulder antibodies showing increased prevalence. Selection and somatic maturation have optimized antibody potency in less-mutated epitopes and recovered potency in highly mutated epitopes. All 27 mAbs potently neutralize early pandemic strains and many show broad reactivity with variants of concern.

Item Type: Article
DOI/Identification number: 10.1016/j.cell.2022.05.014
Subjects: Q Science > QR Microbiology > QR355 Virology
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User: Nigel Temperton
Date Deposited: 24 May 2022 20:52 UTC
Last Modified: 25 May 2022 11:30 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/95166 (The current URI for this page, for reference purposes)
Temperton, Nigel J.: https://orcid.org/0000-0002-7978-3815
  • Depositors only (login required):

Downloads

Downloads per month over past year